Funding to accelerate development of AI-driven tumour profiling tool OneMap One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

fizer is expanding its R&D efforts in China and announced plans to build a new facility. An agreement has been signed to establish a new Pfizer R&D centre in Wuhan, which the firm says represents an ...

Macmillan Cancer Support estimates that cancer affects over three million people in the UK A new policy review produced by cancer doctors and experts from across the UK, including King’s College ...

Alzheimer’s and Parkinson’s disease are responsible for more than 30 million cases globally Lucy Therapeutics (LucyTx) has announced it has raised $12.5m in additional funding to develop potentially ...

For 2025, The 2025 PharmaTimes Clinical Researcher of the Year – The Americas Awards are excited to introduce a new category, Clinical Trial Administrator. This category is designed to assess the ...

The move significantly expands and diversifies AbbVie’s revenue base AbbVie has wrapped up its $63 billion acquisition of Allergan plc following receipt of regulatory approval from all government ...

Prostate cancer is responsible for around 12,000 deaths a year in the UK and is the second biggest cause of death for men Researchers from the Universities of Bristol, Oxford and Cambridge have ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

Three-year trial results reveal long-term improvements in pain and lesion resolution UCB has announced new three-year data from its BE HEARD trials for BIMZELX (bimekizumab-bkzx), showing sustained ...

Early-stage study reveals strong immune response and safety profile for ACI-35.030 AC Immune SA has announced peer-reviewed results from its phase 1b/2a trial of two Tau-targeting active ...